Dramatic Improvement in Physical Well-Being of Terminal AIDS Patients Following Administration of Phytochemicals


Phytochemicals (PHT) are biologically active chemicals produced by plants, non-essential nutrients, with medicinal properties. In this short communication we report the dramatic improvement in the physical and clinical well-being of 9 terminal AIDS patients that received Phyto V7, a PHT mix, for a period of 3 months. All patients living in the Dr. Cruz Jiminian Foundation (hospice) in Santo Domingo, Dominican Republic, were in an emaciated condition—most could not eat, sit down, shower, stand up or dress alone; all had high viremia (from ~50,000 to above 500,000; 243,816 ± 176,724 HIV-1 RNA copies/ml) and very low CD4+ T-cells counts (142 ± 51 counts/mm3). The clinical status of all patients was C3 according to the United States Centers for Disease Control (CDC) status index. As antiretroviral treatment was not available to the Foundation at the time of the study, the only treatment that they received was Phyto V7 supplementation. Each individual received 5 tablets 3 times a day, each tablet containing 750 mg of Phyto V7. At the end of the 3 months, Phyto V7 supplementation radically improved the well-being of all 9 patients. All patients could eat, sit down, shower, stand up and dress alone. This study supports the notion that PHT supplementation can improve significantly the well-being of terminally ill AIDS patients and is the foundation to conducting further control studies to substantiate this notion.

Share and Cite:

M. Díaz, F. Jiminian, R. Wernik, W. Goldman and G. Borkow, "Dramatic Improvement in Physical Well-Being of Terminal AIDS Patients Following Administration of Phytochemicals," World Journal of AIDS, Vol. 3 No. 3, 2013, pp. 287-291. doi: 10.4236/wja.2013.33036.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] T. J. Barber, A. Hughes, W. W. Dinsmore and A. Phillips, “How Does HIV Impact on Non-AIDS Events in the Era of HAART?” International Journal of STD AIDS, Vol. 20, No. 1, 2009, pp. 1-3. doi:10.1258/ijsa.2008.008302
[2] M. A. Hacker, A. Kaida, R. S. Hogg and F. I. Bastos, “The First Ten Years: Achievements and Challenges of the Brazilian Program of Universal Access to HIV/AIDS Comprehensive Management and Care, 1996-2006,” Cadernos de Saúde Pública, Vol. 23, No. S3, 2007, pp. S345-S359.
[3] D. Ogoina et al., “Morbidity and Mortality Patterns of Hospitalised Adult HIV/AIDS Patients in the Era of Highly Active Antiretroviral Therapy: A 4-Year Retrospective Review from Zaria, Northern Nigeria,” AIDS Research and Treatment, Vol. 2012, No. 2012, 2012, Article ID: 940580.
[4] O. Keiser et al., “Adverse Events to Antiretrovirals in the Swiss HIV Cohort Study: Effect on Mortality and Treatment Modification,” Antiviral Therapy, Vol. 12, No. 8, 2007, pp. 1157-1164.
[5] R. J. Zinn, C. Serrurier, S. Takuva, I. Sanne and C. N. Menezes, “HIV-Associated Lipodystrophy in South Africa: The Impact on the Patient and the Impact on the Plastic Surgeon,” Journal of Plastic, Reconstructive & Aesthetic Surgery, Vol. 66, No. 6, 2013, pp. 839-844. doi:10.1016/j.bjps.2013.02.032
[6] J. M. Llibre et al., “The Changing Face of HIV/AIDS in Treated Patients,” Current HIV Research, Vol. 7, No. 4, 2009, pp. 365-377. doi:10.2174/157016209788680633
[7] S. Emamzadeh-Fard, S. E. Fard, S. Seyed Alinaghi and K. Paydary, “Adherence to Anti-Retroviral Therapy and Its Determinants in HIV/AIDS Patients: A Review,” Infectious Disorders Drug Targets, Vol. 12, No. 5, 2012, pp. 346-356. doi:10.2174/187152612804142251
[8] S. Bautista-Arredondo, T. Dmytraczenko, G. Kombe and S. M. Bertozzi, “Costing of Scaling up HIV/AIDS Treatment in Mexico,” Salud Pública de México, Vol. 50, No. S4, 2008, pp. S437-S444.
[9] S. Apanga, D. Punguyire and G. Adjei, “Estimating the Cost to Rural Ambulating HIV/AIDS Patients on Highly Active Antiretroviral Therapy (HAART) in Rural Ghana: A Pilot Study,” The Pan African Medical Journal, Vol. 12, No. 2012, 2012, p. 21.
[10] E. Naik et al., “Cost of Treatment: The Single Biggest Obstacle to HIV/AIDS Treatment Adherence in Lower-Middle Class Patients in Mumbai, India,” Indian Journal of Sexually Transmitted Diseases, Vol. 30, No. 1, 2009, pp. 23-27. doi:10.4103/0253-7184.55476
[11] M. Fantoni et al., “Symptom Profile in Terminally Ill AIDS Patients,” AIDS Patient Care and STDs, Vol. 10, No. 3, 1996, pp. 171-173. doi:10.1089/apc.1996.10.171
[12] M. J. Hommes et al., “Increased Resting Energy Expenditure in Human Immunodeficiency Virus-Infected Men,” Metabolism, Vol. 39, No. 11, 1990, pp. 1186-1190. doi:10.1016/0026-0495(90)90092-Q
[13] J. C. Melchior et al., “Resting Energy Expenditure in Human Immunodeficiency Virus-Infected Patients: Comparison between Patients with and without Secondary Infections,” The American Journal of Clinical Nutrition, Vol. 57, No. 5, 1993, pp. 614-619.
[14] J. C. Melchior et al., “Resting Energy Expenditure Is Increased in Stable, Malnourished HIV-Infected Patients,” The American Journal of Clinical Nutrition, Vol. 53, No. 2, 1991, pp. 437-441.
[15] M. J. Batterham, “Investigating Heterogeneity in Studies of Resting Energy Expenditure in Persons with HIV/ AIDS: A Meta-Analysis,” The American Journal of Clinical Nutrition, Vol. 81, No. 3, 2005, pp. 702-713.
[16] World Health Organization, “Nutrient Requirements for People Living with HIV/AIDS: Report of a Technical Consultation,” 2003.
[17] C. R. Loonam and A. Mullen, “Nutrition and the HIV-Associated Lipodystrophy Syndrome,” Nutrition Research Reviews, Vol. 25, No. 2, 2012, pp. 267-287. doi:10.1017/S0954422411000138
[18] W. W. Fawzi et al., “A Randomized Trial of Multivitamin Supplements and HIV Disease Progression and Mortality,” The New England Journal of Medicine, Vol. 351, No. 1, 2004, pp. 23-32. doi:10.1056/NEJMoa040541
[19] S. Jiamton et al., “A Randomized Trial of the Impact of Multiple Micronutrient Supplementation on Mortality among HIV-Infected Individuals Living in Bangkok,” AIDS, Vol. 17, No. 17, 2003, pp. 2461-2469. doi:10.1097/00002030-200311210-00008
[20] J. D. Kaiser et al., “Micronutrient Supplementation Increases CD4 Count in HIV-Infected Individuals on Highly Active Antiretroviral Therapy: A Prospective, Double-Blinded, Placebo-Controlled Trial,” Journal of Acquired Immune Deficiency Syndromes, Vol. 42, No. 5, 2006, pp. 523-528. doi:10.1097/01.qai.0000230529.25083.42
[21] K. Kawai et al., “A Randomized Trial to Determine the Optimal Dosage of Multivitamin Supplements to Reduce Adverse Pregnancy Outcomes among HIV-Infected Women in Tanzania,” The American Journal of Clinical Nutrition, Vol. 91, No. 2, 2010, pp. 391-397. doi:10.3945/ajcn.2009.28483
[22] R. D. Semba et al., “Micronutrient Supplements and Mortality of HIV-Infected Adults with Pulmonary TB: A Controlled Clinical Trial,” The International Journal of Tuberculosis and Lung Disease, Vol. 11, No. 8, 2007, pp. 854-859.
[23] J. E. Forrester and K. A. Sztam, “Micronutrients in HIV/ AIDS: Is There Evidence to Change the WHO 2003 Recommendations?” The American Journal of Clinical Nutrition, Vol. 94, No. 6, 2011, pp. 1683S-1689S. doi:10.3945/ajcn.111.011999
[24] N. Siegfried, J. H. Irlam, M. E. Visser and N. N. Rollins, “Micronutrient Supplementation in Pregnant Women with HIV Infection,” Cochrane Database of Systematic Reviews, Vol. 3, No. 2012, 2012, Article ID: CD009755.
[25] E. E. Lutge, A. Gray and N. Siegfried, “The Medical Use of Cannabis for Reducing Morbidity and Mortality in Patients with HIV/AIDS,” Cochrane Database of Systematic Reviews, Vol. 4, No. 2013, Article ID: CD005175.
[26] X. Kong, G. Wu and Y. Yin, “Roles of Phytochemicals in Amino Acid Nutrition,” Frontiers in Bioscience (Scholar Edition), Vol. 3, No. 2011, 2011, pp. 372-384.
[27] B. Holst and G. Williamson, “Nutrients and Phytochemicals: From Bioavailability to Bioefficacy beyond Antioxidants,” Current Opinion in Biotechnology, Vol. 19, No. 2, 2008, pp. 73-82. doi:10.1016/j.copbio.2008.03.003
[28] X. Wang et al., “Phytochemicals and Biological Studies of Plants from the Genus Balanophora,” Chemistry Central Journal, Vol. 6, No. 1, 2012, p. 79. doi:10.1186/1752-153X-6-79
[29] L. Z. Sun, N. L. Currier and S. C. Miller, “The American Coneflower: A Prophylactic Role Involving Nonspecific Immunity,” Journal of Alternative and Complementary Medicine, Vol. 5, No. 5, 1999, pp. 437-446. doi:10.1089/acm.1999.5.437
[30] B. B. Aggarwal and S. Shishodia, “Suppression of the Nuclear Factor-KappaB Activation Pathway by Spice-Derived Phytochemicals: Reasoning for Seasoning,” Annals of the New York Academy of Sciences, Vol. 1030, No. 2004, 2004, pp. 434-441.
[31] E. G. de Mejia and M. V. Ramirez-Mares, “Ardisia: Health-Promoting Properties and Toxicity of Phytochemicals and Extracts,” Toxicology Mechanisms and Methods, Vol. 21, No. 9, 2011, pp. 667-674. doi:10.3109/15376516.2011.601355
[32] B. N. Rao, “Bioactive Phytochemicals in Indian Foods and Their Potential in Health Promotion and Disease Prevention,” Asia Pacific Journal of Clinical Nutrition, Vol. 12, No. 1, 2003, pp. 9-22.
[33] D. O. Kennedy and E. L. Wightman, “Herbal Extracts and Phytochemicals: Plant Secondary Metabolites and the Enhancement of Human Brain Function,” Advances in Nutrition, Vol. 2, No. 1, 2011, pp. 32-50. doi:10.3945/an.110.000117
[34] G. P. Kumar and F. Khanum, “Neuroprotective Potential of Phytochemicals,” Pharmacognosy Reviews, Vol. 6, No. 12, 2012, pp. 81-90.
[35] M. H. Traka and R. F. Mithen, “Plant Science and Human Nutrition: Challenges in Assessing Health-Promoting Properties of Phytochemicals,” Plant Cell, Vol. 23, No. 7, 2011, pp. 2483-2497. doi:10.1105/tpc.111.087916
[36] S. Rajaram, “The Effect of Vegetarian Diet, Plant Foods, and Phytochemicals on Hemostasis and Thrombosis,” The American Journal of Clinical Nutrition, Vol. 78, No. S3, 2003, pp. 552S-558S.
[37] G. Bagalkotkar, S. R. Sagineedu, M. S. Saad and J. Stanslas, “Phytochemicals from Phyllanthus Niruri Linn and Their Pharmacological Properties: A Review,” Journal of Pharmacy and Pharmacology, Vol. 58, No. 12, 2006, pp. 1559-1570. doi:10.1211/jpp.58.12.0001
[38] A. Imaz, V. Falco and E. Ribera, “Antiretroviral Salvage Therapy for Multiclass Drug-Resistant HIV-1-Infected Patients: From Clinical Trials to Daily Clinical Practice,” AIDS Reviews, Vol. 13, No. 3, 2011, pp. 180-193.
[39] J. F. Senise, A. Castelo and M. Martinez, “Current Treatment Strategies, Complications and Considerations for the Use of HIV Antiretroviral Therapy during Pregnancy,” AIDS Reviews, Vol. 13, No. 4, 2011, pp. 198-213.
[40] C. A. Shah, “Adherence to High Activity Antiretrovial Therapy (HAART) in Pediatric Patients Infected with HIV: Issues and Interventions,” Indian Journal of Pediatrics, Vol. 74, No. 1, 2007, pp. 55-60. doi:10.1007/s12098-007-0028-8
[41] R. Subbaraman, S. K. Chaguturu, K. H. Mayer, T. P. Flanigan and N. Kumarasamy, “Adverse Effects of Highly Active Antiretroviral Therapy in Developing Countries,” Clinical Infectious Diseases, Vol. 45, No. 8, 2007, pp. 1093-1101. doi:10.1086/521150
[42] O. R. Obiako and H. M. Muktar, “Challenges of HIV Treatment in Resource-Poor Countries: A Review,” Nigerian Medical Journal, Vol. 19, No. 4, 2010, pp. 361-368. doi:10.4314/njm.v19i4.69785

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.